In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Business Strategies Leadership

In Bid For Genentech, How High Can Roche Go?

Executive Summary

Roche's effort to clinch a buy-out of Genentech has moved to a new, critical stage of negotiations. But just how much can Roche afford to pay for the top-of-the-line biotech, which comes with A-list scientific talent, an extensive pipeline heavily weighted in the lucrative arena of oncology, and a price tag to match?
Table

View full table

Advertisement

Related Content

In Vivo
Roche/Genentech: A Case Study For Future Hostile Offers
In Vivo
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
In Vivo
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
In Vivo
Credit Woes Hit Pharma
In Vivo
Credit Woes Hit Pharma
In Vivo
ImClone and Bristol: The Acquisition Fight Focuses on the Erbitux Successor
Scrip
Roche's Acquisition of Genentech: Retention Program Unlikely to Stem Departures
In Vivo
ImClone and Bristol: The Acquisition Fight Focuses on the Erbitux Successor
In Vivo
After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation
In Vivo
After Roche/Genentech: Pharma's Focus on Efficiencies, Not Innovation

Topics

Related Companies

Related Deals

Advertisement
Tags:
BioPharmaceutical Business Strategies Leadership
UsernamePublicRestriction

Register

IV003169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By